Abbott Norvir Cost Chart Misrepresents Therapeutic Dose, Price – FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The pricing chart, created to explain a 2003 price increase, compares the cost of Norvir 100 mg daily to higher, labeled doses of other protease inhibitors, and implies that Norvir may be used as a monotherapy at a low dose, FDA said. The agency previously sent Abbott a letter citing Norvir promotional materials in 2001.
You may also be interested in...
Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says
A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.
Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says
A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.